| Date Filed | Type | Description |
| 10/10/2023 |
6-K
| Quarterly results |
| 08/24/2023 |
6-K
| Quarterly results|
Docs:
|
"REPORT OF FOREIGN PRIVATE ISSUER",
"CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million ● Received in July 2023, $10 million from partner, AbbVie, for achieving a major milestone in the second quarter, for the clinical-phase dermal filler product in accordance with the strategic collaboration agreement ● Entered into collaboration with Stratasys, a world-leading 3D printing company, with initial focus on the development of a bioprinting solution for the fabrication of CollPlant’ s regenerative breast implants ● Readying breast implant study in large animals for initiation by year end ● Continued positive sales trajectory for 3D bioinks ● Cash and cash equivalents totaled $22.3 million as of June 30, 2023; cash runway extended with addition...",
"COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023",
"OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF JUNE 30, 2023" |
|
| 07/24/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 07/18/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 06/08/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 05/24/2023 |
6-K
| Quarterly results |
| 04/18/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 04/04/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 03/29/2023 |
6-K
| Quarterly results |
| 03/29/2023 |
20-F
| Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: |
| 02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/30/2023 |
SC 13G/A
| INVESTMENT MANAGEMENT OF VIRGINIA LLC reports a 4.9% stake in COLLPLANT BIOTECHNOLOGIES LTD. |
| 01/25/2023 |
SC 13G/A
| Loewenbaum Lilian S. reports a 8% stake in CollPlant Biotechnologies Ltd. |
| 01/24/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 01/13/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/11/2023 |
SC 13G/A
| MEITAV DASH INVESTMENTS LTD reports a 5.5% stake in CollPlant Biotechnologies Ltd |
| 01/06/2023 |
DEL AM
| Form DEL AM - Delaying amendment: |
| 01/04/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 01/03/2023 |
6-K
| Quarterly results |
| 12/30/2022 |
F-3
| Form F-3 - Registration statement by foreign private issuers: |
| 12/01/2022 |
6-K
| Quarterly results |
| 11/17/2022 |
6-K
| Quarterly results |
| 11/15/2022 |
6-K
| Quarterly results |
| 11/07/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 08/26/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 08/25/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"REPORT OF FOREIGN PRIVATE ISSUER",
"CollPlant Biotechnologies Provides Business Updates and Second Quarter 2022 Financial Results · Co-development of rhCollagen-based dermal and soft tissue fillers with AbbVie is progressing · Company’ s 3D bioprinted regenerative breast implant program remains on track to conclude large animal study in Q4 · Development of aseptic process for the production of sterile rhCollagen anticipated to be completed in Q4 · Strong balance sheet with cash and cash equivalents of $36M as of June 30, 2022 Rehovot, Israel August 25, 2022 -- CollPlant Biotechnologies , a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced financial results for the second ...",
"COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022",
"OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF JUNE 30, 2022" |
|
| 06/29/2022 |
6-K
| Quarterly results |
| 05/26/2022 |
6-K
| Quarterly results |
| 05/02/2022 |
6-K
| Quarterly results |
| 04/14/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 03/25/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/25/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 03/24/2022 |
20-F
| Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: |
| 03/24/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
|